Scholars@Duke publication: Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B).

Journal cover image

Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B).

Publication , Conference

Ryan, CJ; Dutta, S; Kelly, W; Morris, MJ; Taplin, M-E; Halabi, S

Published in: Ann Oncol

October 2018

Published version (DOI) Link to item

Duke Scholars

Author Susan Halabi Biostatistics & Bioinformatics, Division of Biostatistics

Published In

Ann Oncol

DOI

10.1093/annonc/mdy284.025

EISSN

1569-8041

Publication Date

October 2018

Volume

29 Suppl 8

Start / End Page

viii283

Location

England

Related Subject Headings

Oncology & Carcinogenesis
3211 Oncology and carcinogenesis
3202 Clinical sciences
1112 Oncology and Carcinogenesis

Citation

APA

Chicago

ICMJE

MLA

NLM

Ryan, C. J., Dutta, S., Kelly, W., Morris, M. J., Taplin, M.-E., & Halabi, S. (2018). Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B). In Ann Oncol (Vol. 29 Suppl 8, p. viii283). England. https://doi.org/10.1093/annonc/mdy284.025

Ryan, C. J., S. Dutta, W. Kelly, M. J. Morris, M. -. E. Taplin, and S. Halabi. “Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B).” In Ann Oncol, 29 Suppl 8:viii283, 2018. https://doi.org/10.1093/annonc/mdy284.025.

Ryan CJ, Dutta S, Kelly W, Morris MJ, Taplin M-E, Halabi S. Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B). In: Ann Oncol. 2018. p. viii283.

Ryan, C. J., et al. “Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B).” Ann Oncol, vol. 29 Suppl 8, 2018, p. viii283. Pubmed, doi:10.1093/annonc/mdy284.025.

Ryan CJ, Dutta S, Kelly W, Morris MJ, Taplin M-E, Halabi S. Androgen decline and outcome in castration resistant prostate cancer (mCRPC) patients treated with docetaxel (Doc), prednisone +/- bevacizumab (B). Ann Oncol. 2018. p. viii283.

Journal cover image

Published In

Ann Oncol

DOI

10.1093/annonc/mdy284.025

EISSN

1569-8041

Publication Date

October 2018

Volume

29 Suppl 8

Start / End Page

viii283

Location

England

Related Subject Headings

Oncology & Carcinogenesis
3211 Oncology and carcinogenesis
3202 Clinical sciences
1112 Oncology and Carcinogenesis